Skip to main content

Table 1 Background characteristics and treatment outcomes of the subjects

From: 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy

Subject Age/Sex Baseline ICG features Number of Half-dose PDT BCVA (logMAR) Number of ranibizumab injections ICG findings at 12-month Complications
Baseline 3-month 6-month 12-month Polyp BVN  
1 60/F 1 polyp 1 0.7 0.4 0.3 0.3 3 Regressed / Nil
2 60/F 1 polyp 1 1.0 0.55 0.3 0.3 3 Regressed / Nil
3 77/M 1 polyp 1 0.3 0.3 0.2 0.2 2 Regressed / Nil
4 68/F 1 polyp 1 0.3 0.3 0.4 0.3 4 Regressed / Nil
5 66/M 1 polyp 1 0.0 0.1 0.0 0.1 1 Regressed / Nil
6 71/M 1 polyp 1 0.1 0.1 0.1 0.1 1 Regressed / Nil
7 55/M 1 polyp 1 1.3 0.4 0.4 0.4 2 Regressed / Nil
8 63/M 2 polyps 1 0.7 0.4 0.4 0.3 1 Regressed / Nil
9 52/F 2 polyps 2 1.0 0.7 0.7 0.6 2 Regressed / Nil
10 88/M 2 polyps 2 0.55 0.4 0.4 0.4 2 Regressed / Nil
11 78/M 2 polyps 2 0.7 0.4 0.3 0.4 2 Regressed / Nil
12 75/F 2 polyps 2 0.55 0.3 0.4 0.3 1 Regressed / Nil
13 60/F 5 polyps 2 1.0 0.7 1.0 1.0 7 Regressed / Nil
14 69/M BVN + 2 polyps 2 0.4 0.4 0.55 0.4 2 Regressed Persisted Nil
15 72/F BVN + 2 polyps 2 0.7 0.7 0.55 0.55 2 Regressed Persisted Nil
16 55/F BVN + 2 polyps 3 1.3 1.0 1.0 1.0 5 Regressed Persisted Nil
17 84/F BVN + 2 polyps 2 0.3 0.3 0.4 0.3 1 Regressed Persisted Nil
18 76/M BVN + 3 polyps 2 0.55 0.4 0.3 0.3 2 Regressed Persisted Nil
19 81/M BVN + 5 polyps 2 0.7 0.4 0.55 0.55 2 Regressed Persisted Nil